Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108193 - LYOPHILIZED PREPARATION FOR PROSTAGLANDIN E1 METHYL ESTER INJECTION, PREPARATION THEREOF AND APPLICATION THEREOF

Publication Number WO/2020/108193
Publication Date 04.06.2020
International Application No. PCT/CN2019/113557
International Filing Date 28.10.2019
IPC
A61K 9/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
A61K 9/107 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
A61K 31/5575 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
5575having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 47/44 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42107; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 7/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 9/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
08Vasodilators for multiple indications
CPC
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 47/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61K 9/107
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions ; ; Emulsion preconcentrates; Micelles
A61K 9/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
19lyophilised ; , i.e. freeze-dried, solutions or dispersions
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applicants
  • 西安力邦肇新生物科技有限公司 XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD. [CN]/[CN]
Inventors
  • 王汝涛 WANG, Rutao
  • 安龙 AN, Long
  • 赵熠 ZHAO, Yi
  • 庞菁华 PANG, Jinghua
  • 陈涛 CHEN, Tao
Agents
  • 北京三友知识产权代理有限公司 BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD.
Priority Data
201811423561.727.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) LYOPHILIZED PREPARATION FOR PROSTAGLANDIN E1 METHYL ESTER INJECTION, PREPARATION THEREOF AND APPLICATION THEREOF
(FR) PRÉPARATION LYOPHILISÉE SERVANT À L'INJECTION D'ESTER MÉTHYLIQUE DE PROSTAGLANDINE E1, SA PRÉPARATION ET SON APPLICATION
(ZH) 一种前列腺素E1甲酯注射用冻干制剂及制备和应用
Abstract
(EN)
Provided are a lyophilized preparation for prostaglandin E1 methyl ester injection, a preparation thereof and an application thereof. The lyophilized preparation comprises the following components in parts by weight: 0.1-10 parts of prostaglandin E1 methyl ester, 500-4,000 parts of oil for injection, 500-2,000 parts of an emulsifier, 0-10 parts of a co-emulsifier, 5,000-50,000 parts of a lyoprotectant, and 200-1,500 parts of glycerol. The prostaglandin E1 methyl ester lyophilized preparation has small vascular stimulation and good drug stability.
(FR)
L'invention concerne une préparation lyophilisée servant à l'injection d'un ester méthylique de prostaglandine E1, sa préparation et son application. La préparation lyophilisée comprend les composants suivants en parties en poids : 0,1 À 10 parties d'ester méthylique de prostaglandine E1, 500 à 4 000 parties d'huile servant à l'injection, 500 à 2000 parties d'un émulsifiant, 0 à 10 parties d'un co-émulsifiant, 5 000 à 50 000 parties d'un lyoprotecteur, et 200 à 1 500 parties de glycérol. La préparation lyophilisée d'ester méthylique de prostaglandine E1 a une faible stimulation vasculaire et une bonne stabilité de médicament.
(ZH)
提供一种前列腺素E1甲酯注射用冻干制剂及制备和应用。所述冻干制剂包括如下重量份成分:前列腺素E1甲酯0.1-10份、注射用油500-4000份、乳化剂500-2000份、助乳化剂0-10份、冻干保护剂5000-50000份、以及甘油200-1500份。所述前列腺素E1甲酯冻干剂具有血管刺激小、药物稳定性好。
Also published as
Latest bibliographic data on file with the International Bureau